Akeso Inc. has announced that the National Medical Products Administration (NMPA) has accepted its supplementary New Drug Application (sNDA) for ivonescimab, a PD-1/VEGF bispecific antibody, in combination with chemotherapy as a first-line treatment for advanced squamous non-small cell lung cancer. This marks the third accepted application for ivonescimab in China, building on previous submissions for its use in other forms of non-small cell lung cancer. The decision is based on positive outcomes from the Phase III HARMONi-6 study, which demonstrated the superiority of ivonescimab combined with chemotherapy over existing treatments. Ivonescimab is currently involved in several clinical trials worldwide, further establishing its role in global cancer immunotherapy.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。